AnaptysBio(ANAB) - 2025 Q2 - Quarterly Results

PORTFOLIO UPDATES Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update SAN DIEGO, August 6, 2025 — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "Rosnilimab's Phase 2b data in rheumatoid arthritis (RA) delivered a compelling safety and tolerability profile and JAK- like efficacy through ...